Phase III trials
Chemotherapy VS EGFR-TKI
EGFR-TKI
N
ORR
Median
PFS
Mok TS, 2009
[IPASS]
Gefitinib
132
71%
9.5 m
Maemondo M, 2010
[NEJ002]
Gefitinib
114
74%
10.8 m
Mitsudomi T, 2010
[WJTOG3405]
Gefitinib
86
62%
9.6 m
Zhou C, 2011
[OPTIMAL]
Erlotinib
82
83%
13.1 m
Russell R, 2012
[EUROTAC]
Erlotinib
86
58%
9.7 m
Sequist LV, 2013
[LUX-Lung 3]
Afatinib
230
56%
13.6 m*
Wu YL, 2013
[LUX-Lung 6]
Afatinib
242
67%
11 m
Efficacy summary of EGFR-TKIs in
1L advanced NSCLC
* L858R and Del 19 mutations
EGFR TKI doubles the ORR and PFS compared to a platin doublet
